ArticleThe Lancet regional health. Western Pacific2026
Real-world effectiveness of nirsevimab against RSV hospitalisation in infants during a season with low coverage and delayed circulation in Beijing, China: a population-based retrospective cohort study.
Article in The Lancet regional health. Western Pacific, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- RSV prophylactics for pediatric populations: A product review and meta-analysis of real-world effectiveness.Human vaccines & immunotherapeutics · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nirsevimab was first deployed in Beijing through a pilot voluntary, self-pay scheme during the 2024-2025 epidemic season, following its approval in China in December 2023. We aimed to evaluate the real-world effectiveness of nirsevimab against RSV-associated lower respiratory tract infection (LRTI) hospitalisation in Beijing, China. Methods: We conducted a population-based retrospective cohort study using linked, individual-level data from the Beijing Immunisation Information System and Hospitalisation Information System. The study population comprised all infants born between April 1, 2024, and March 31, 2025, in 24 designated pilot maternity hospitals. The primary endpoint was RSV-associated LRTI hospitalisation. City-wide virological surveillance was used to define the population-level exposure risk period. Nirsevimab effectiveness was estimated using Bayesian Poisson regression in a propensity score-matched cohort, with three additional models (Firth penalized Poisson, Bayesian Cox, and Firth penalized Cox) as sensitivity analyses. Findings: Among 44,791 eligible infants, 1166 (2.6%) received nirsevimab. In the propensity score-matched cohort (1129 infants per group), the incidence rates of RSV-associated LRTI hospitalisation were 18.8 vs. 2.3 per 1000 person-years in non-recipients and recipients, respectively. Bayesian Poisson regression demonstrated 83.3% effectiveness (95% CrI: 33.3-97.5%; posterior probability: 0.995). Sensitivity analyses yielded consistent estimates (82.8-84.5%). Analyses in the full cohort produced directionally consistent estimates. Interpretation: This first evidence of nirsevimab's effectiveness in China validates its value in a novel geographical and implementation context, supporting its inclusion as a recommended preventive option. Real-time virological surveillance is essential to optimise immunisation timing amid evolving RSV epidemiology. Funding: Capital's Funds for Health Improvement and Research (2026-1G-3012); Beijing Research Center for Respiratory Infectious Diseases (BJRID2024-002); Beijing Municipal Health Commission's Funds for the High-qualified Public Health Professionals Development Project (Discipline Core-03-36); Capital's Funds for Health Improvement and Research (2024-2-30117).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.